Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Increases By 30.7%

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 597,300 shares, a growth of 30.7% from the December 15th total of 457,100 shares. Approximately 22.4% of the shares of the company are short sold. Based on an average daily trading volume, of 421,900 shares, the days-to-cover ratio is currently 1.4 days.

Institutional Investors Weigh In On Aligos Therapeutics

An institutional investor recently raised its position in Aligos Therapeutics stock. Acadian Asset Management LLC boosted its position in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 26.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 829,485 shares of the company’s stock after purchasing an additional 171,490 shares during the period. Acadian Asset Management LLC owned about 1.06% of Aligos Therapeutics worth $289,000 at the end of the most recent quarter. Institutional investors own 60.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a report on Thursday, November 7th.

Aligos Therapeutics Stock Down 0.4 %

Shares of ALGS opened at $31.61 on Friday. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $46.80. The stock has a market cap of $113.48 million, a price-to-earnings ratio of -2.37 and a beta of 2.50. The company has a 50-day moving average price of $30.29 and a two-hundred day moving average price of $17.82.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The company had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. During the same quarter last year, the business earned ($10.25) EPS. Equities research analysts expect that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).